Loading...
XSHE
002219
Market cap1.07bUSD
Dec 05, Last price  
2.32CNY
1D
1.75%
1Q
5.94%
Jan 2017
-80.63%
IPO
17.45%
Name

New Journey Health Technology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002219 chart
P/E
65.83
P/S
1.99
EPS
0.04
Div Yield, %
Shrs. gr., 5y
12.01%
Rev. gr., 5y
0.61%
Revenues
3.80b
+5.81%
100,225,011130,103,412198,231,917284,972,508285,116,048299,331,669307,244,763336,964,448564,725,360685,657,6501,181,728,2232,175,221,1873,399,324,1433,838,392,1973,684,467,7212,805,895,4943,016,070,7333,152,734,8803,590,482,0603,799,010,313
Net income
115m
+272.90%
17,578,34219,257,95433,796,74544,511,22547,805,40765,961,42971,345,72673,672,375169,827,048257,332,861323,626,317403,631,489202,809,2630000156,121,50230,776,551114,765,521
CFO
439m
+50.70%
36,535,83013,549,75231,880,72122,369,35632,627,52664,425,81594,803,99382,705,472158,400,972193,353,694219,021,90300522,565,203549,512,401283,796,318277,294,763268,039,414290,977,690438,505,853
Dividend
Feb 28, 20140.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hengkang Medical Group Co.,Ltd provides medical services, pharmaceuticals, health care, and daily chemical products in China and internationally. It operates approximately 11 hospitals. The company also manufactures pharmaceutical products in the areas of analgesia, cold, cough, gynecology, cardiovascular, digestive, and urinary systems. In addition, it offers Chinese herbal medicines, infusion, and hemostasis products, as well as daily chemical products. The company was formerly known as Gansu Duyiwei Biological Pharmaceutical Co., Ltd. and changed its name to Hengkang Medical Group Co.,Ltd in January 2014. Hengkang Medical Group Co.,Ltd. was founded in 2001 and is based in Chengdu, China.
IPO date
Mar 06, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT